Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Pfizer stopped developing danuglipron, a daily oral obesity drug, due to a patient's potential liver injury during the trial.

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.“I’ve argued for a long time that for phase 1 ...

Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This mi ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...